Aligos Therapeutics vs NRX Pharmaceuticals
Aligos Therapeutics is the larger business, with $2.2m of revenue in fiscal 2025 against $1.2m for NRX Pharmaceuticals (1.8 times as much). Aligos Therapeutics kept more of each dollar of sales as profit: a net margin of -1106.7% against -2336.5%.
| Latest fiscal year | Aligos TherapeuticsALGS, 2025 | NRX PharmaceuticalsNRXP, 2025 |
|---|---|---|
| Revenue | $2.2m | $1.2m |
| Revenue growth | -39.5% | — |
| Net income | −$24.2m | −$28.6m |
| Operating margin | — | — |
| Net margin | -1106.7% | -2336.5% |
| Return on equity | -196.9% | — |
| Free cash flow | −$82.5m | −$14.1m |
| Cash | $18.3m | $7.8m |
| Total debt | $0 | $0 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 82 | 29 |
| Market value | $29.6m | $100m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |